In Israel, high honors for Feinstein’s diabetes warrior
By GREGORY ZELLER // A Feinstein Institutes for Medical Research professor who’s dedicated his life to battling diabetes has earned a rare honor. Endocrinologist Jesse Roth, a fellow of the…
Kevin Tracey
No. 429: Classic cartoons, downtown dreams and the nitrogen nuisance – plus, it curves!
Middle ground: It’s Wednesday, dear readers, and you’re halfway through this latest summery week of socioeconomic innovation. Keep it up. Today is Aug. 14, and if you had the…
Writing the book, literally, on bioelectronic medicine
By GREGORY ZELLER // The pioneering work of several key researchers has made Long Island a focal point in the emerging science of bioelectronic medicine – their combined knowledge and…
Tracey, global team unearth new bioelectronic clue
By GREGORY ZELLER // An international research team featuring one of Long Island’s great innovators has uncovered a potential key to fighting viral infections – a bioelectronic-medicine breakthrough with wide-ranging…
Top psychologist to lead new behavioral-health center
By GREGORY ZELLER // A highly credentialed expert in the psychological and social risk factors influencing cardiovascular disease will head the Feinstein Institute for Medical Research’s new behavioral-health center. Karina…
NIH gets behind new Feinstein Institute sepsis study
By GREGORY ZELLER // A five-year National Institutes of Health grant will pack the protein into a new Long Island sepsis study. Monowar Aziz, an assistant professor at the Manhasset-based…
On the right path in Feinstein Parkinson’s pursuit
By GREGORY ZELLER // A new gene therapy can literally rewire the brains of Parkinson’s disease patients – and may rewrite the book on treatment of the nation’s second most-common…
NIH to Feinstein: Stick out that chest (bioelectrically)
By GREGORY ZELLER // With new treatments for obesity, heart failure and a host of other conditions in sight, a Feinstein Institute researcher will zero in on specific abdominal targets…
Northwell team beats hypofractionation’s drum
By GREGORY ZELLER // From the You Don’t Have to Cut to Cure file comes new research suggesting that a specific form of radiation therapy, previously thought to be ineffective…
No. 332: Hitting it big in vagus, hitting it bigger at SBU, commercial support for the disabled and eternal respect for Aretha
Well done: It’s Friday, dear readers, and once again, you’ve conquered the five-day minefield that is the American workweek. To mark your achievement and put you in a proper Friday…
Nerve-stim startup Sanguistat shuffles its deck
By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized…
Feinstein ‘risk index’ could get the jump on lupus
By GREGORY ZELLER // A complex research effort led by top Feinstein Institute scientists has opened the door to a wide range of early-intervention protocols for the dreaded disease lupus….
How to speak cytokine: a bioelectronics breakthrough
By GREGORY ZELLER // You can bet they didn’t use secret decoder rings. In a major feat of bioengineering and neurological science, a team of doctors at Northwell Health’s Feinstein…
No. 300: Anniversary edition, starring Shakespeare, Dutch Reagan and Academy Award-winner Jessica Lange (and introducing Vengo)
An imperfect 300: Welcome, friends, to your latest Innovate LI newsletter, and not just any Innovate LI newsletter, but the 300th since founder John Kominicki e-blasted the first more than…
Debrief: Feinstein’s busy Bouton strengthens his grip
It’s been a busy two years since Chad Bouton left independent R&D giant Battelle and hitched his wagon to the Feinstein Center for Medical Research, joining forces with bioelectronics pioneer…